Morillo V, Guinot J L, Tortajada I, Ricós J V, Arribas L, Maroñas M, Estornell M, Casanova J
Radiation Oncology Department, F. Instituto Valenciano de Oncología, Valencia, Spain.
Clin Transl Oncol. 2008 Jun;10(6):359-66. doi: 10.1007/s12094-008-0212-y.
To retrospectively evaluate the toxicity of low-dose-rate brachytherapy and to relate it to the dose-volume to organs at risk.
We study 160 patients with early prostate cancer, treated with (125)-I implants. Most of them were T1c (63.1%), T2a (35.6%) and Gleason < or =6 (96.2%). Median PSA was 7.2 ng/ml (2.3-13.5); 85.6% were lowrisk cases and 14.4% high-risk cases. Mean follow-up was 24 months (7-48).
Acute urinary toxicity related to urological quality of life (UQL=CVU) was tolerable in 75% and unsatisfactory in 25%. Urinary retention was present in 6.9%. IPSS, V100 and D90 were related to the urinary toxicity grade. Rectal toxicity (RTOG) G2 was 0.6%. Sexual potency showed no changes with regard to the basal in 69%. Actuarial biochemical control was 89.8% at four years.
Brachytherapy with (125)-I seeds yields acceptable toxicity and excellent biochemical control.
